Skip to content

Study · Animal study (in vivo) · mouse · 2018

9 results

THE ROLE OF MITOCHONDRIAL ENERGETICS IN CARDIAC AND SKELETAL MUSCLE AGING

Rabinovitch P, Marcinek D

Innovation in aging1 Nov 2018

PMCIDPMC6227127 (opens in a new tab)PepBankPUB-90386926
Source linkSource pageAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    Brief treatment with elamipretide improved skeletal muscle ATP generation.

    In plain wordsShort treatment with elamipretide improved the energy output of skeletal muscle. The abstract does not name the species.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSkeletal muscle ATP generation
    Study

    n: not reported in source

    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We have shown that brief treatment with elamipretide improves skeletal muscle ATP generation and fatigue resistance.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    Brief treatment with elamipretide improved skeletal muscle fatigue resistance.

    In plain wordsShort treatment with elamipretide made muscle resist fatigue better. The abstract does not name the species.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSkeletal muscle fatigue resistance
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We have shown that brief treatment with elamipretide improves skeletal muscle ATP generation and fatigue resistance.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In aged mice, a single exposure to elamipretide reduced proton leak in cardiomyocytes and skeletal muscle.

    In plain wordsIn old mice, one exposure to elamipretide lowered proton leak in heart cells and skeletal muscle.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseProton leak in cardiomyocytes and skeletal muscle
    Study

    mousen: not reported in source

    aged mice
    Outcome group
    Mitochondrial function · Aging and longevity
    Studied dose
    Dose not stated · single exposureAs given in this study (mouse).

    Source sentences

    Summary
    Reduced proton leak is observed in both cardiomyocytes and skeletal muscles from aged mice after a single exposure.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In 24-26 month old mice, 8 weeks of SS‑31 improved skeletal muscle energetics.

    In plain wordsIn old mice, 8 weeks of SS‑31 improved the energy use of skeletal muscle.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSkeletal muscle energetics
    Study

    mousen: not reported in source

    aged mice
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    24–26 month old mice that receive SS-31 for 8 weeks have improved skeletal muscle energetics, function and endurance, enhanced cardiac diastolic function, improved myocardial performance, reduced cardiac hypertrophy and increased exercise endurance.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In 24-26 month old mice, 8 weeks of SS‑31 improved skeletal muscle function.

    In plain wordsIn old mice, 8 weeks of SS‑31 improved skeletal muscle function.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSkeletal muscle function
    Study

    mousen: not reported in source

    aged mice
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    24–26 month old mice that receive SS-31 for 8 weeks have improved skeletal muscle energetics, function and endurance, enhanced cardiac diastolic function, improved myocardial performance, reduced cardiac hypertrophy and increased exercise endurance.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In 24-26 month old mice, 8 weeks of SS‑31 improved endurance and increased exercise endurance.

    In plain wordsIn old mice, 8 weeks of SS‑31 improved endurance and exercise endurance.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseEndurance and exercise endurance
    Study

    mousen: not reported in source

    aged mice
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    24–26 month old mice that receive SS-31 for 8 weeks have improved skeletal muscle energetics, function and endurance, enhanced cardiac diastolic function, improved myocardial performance, reduced cardiac hypertrophy and increased exercise endurance.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In 24-26 month old mice, 8 weeks of SS‑31 enhanced cardiac diastolic function.

    In plain wordsIn old mice, 8 weeks of SS‑31 improved how well the heart relaxes.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseCardiac diastolic function
    Study

    mousen: not reported in source

    aged mice
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    24–26 month old mice that receive SS-31 for 8 weeks have improved skeletal muscle energetics, function and endurance, enhanced cardiac diastolic function, improved myocardial performance, reduced cardiac hypertrophy and increased exercise endurance.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In 24-26 month old mice, 8 weeks of SS‑31 improved myocardial performance.

    In plain wordsIn old mice, 8 weeks of SS‑31 improved heart muscle performance.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMyocardial performance
    Study

    mousen: not reported in source

    aged mice
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    24–26 month old mice that receive SS-31 for 8 weeks have improved skeletal muscle energetics, function and endurance, enhanced cardiac diastolic function, improved myocardial performance, reduced cardiac hypertrophy and increased exercise endurance.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In 24-26 month old mice, 8 weeks of SS‑31 reduced cardiac hypertrophy.

    In plain wordsIn old mice, 8 weeks of SS‑31 reduced thickening of the heart muscle.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseCardiac hypertrophy
    Study

    mousen: not reported in source

    aged mice
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 8 weeksAs given in this study (mouse).

    Source sentences

    Summary
    24–26 month old mice that receive SS-31 for 8 weeks have improved skeletal muscle energetics, function and endurance, enhanced cardiac diastolic function, improved myocardial performance, reduced cardiac hypertrophy and increased exercise endurance.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.